248 related articles for article (PubMed ID: 36494311)
1. Impact of tissue-agnostic approvals for patients with gastrointestinal malignancies.
Bhamidipati D; Subbiah V
Trends Cancer; 2023 Mar; 9(3):237-249. PubMed ID: 36494311
[TBL] [Abstract][Full Text] [Related]
2. Impact of tissue-agnostic approvals for patients with sarcoma.
Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
[TBL] [Abstract][Full Text] [Related]
3. Impact of tissue-agnostic approvals on management of primary brain tumors.
Ahluwalia MS; Khosla AA; Ozair A; Gouda MA; Subbiah V
Trends Cancer; 2024 Mar; 10(3):256-274. PubMed ID: 38245379
[TBL] [Abstract][Full Text] [Related]
4. Agnostic Approvals in Oncology: Getting the Right Drug to the Right Patient with the Right Genomics.
Tateo V; Marchese PV; Mollica V; Massari F; Kurzrock R; Adashek JJ
Pharmaceuticals (Basel); 2023 Apr; 16(4):. PubMed ID: 37111371
[TBL] [Abstract][Full Text] [Related]
5. If it's a target, it's a pan-cancer target: Tissue is not the issue.
Adashek JJ; Kato S; Sicklick JK; Lippman SM; Kurzrock R
Cancer Treat Rev; 2024 Apr; 125():102721. PubMed ID: 38522181
[TBL] [Abstract][Full Text] [Related]
6. Evolution of the Targeted Therapy Landscape for Cholangiocarcinoma: Is Cholangiocarcinoma the 'NSCLC' of GI Oncology?
Gupta A; Kurzrock R; Adashek JJ
Cancers (Basel); 2023 Mar; 15(5):. PubMed ID: 36900367
[TBL] [Abstract][Full Text] [Related]
7. Molecular targets in GI malignancies - A pathologist's perspective.
Pawar S; Sharma A
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
[TBL] [Abstract][Full Text] [Related]
8. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
[TBL] [Abstract][Full Text] [Related]
9. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
[TBL] [Abstract][Full Text] [Related]
10. [Current Status and Challenges in Tumor Agnostic Treatment].
Komine K
Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
[TBL] [Abstract][Full Text] [Related]
11. Agnostic Administration of Targeted Anticancer Drugs: Looking for a Balance between Hype and Caution.
Aleksakhina SN; Ivantsov AO; Imyanitov EN
Int J Mol Sci; 2024 Apr; 25(7):. PubMed ID: 38612902
[TBL] [Abstract][Full Text] [Related]
12. Developing Drugs for Tissue-Agnostic Indications: A Paradigm Shift in Leveraging Cancer Biology for Precision Medicine.
Seligson ND; Knepper TC; Ragg S; Walko CM
Clin Pharmacol Ther; 2021 Feb; 109(2):334-342. PubMed ID: 32535906
[TBL] [Abstract][Full Text] [Related]
13. Precision Medicine of Hepatobiliary and Pancreatic Cancers: Focusing on Clinical Trial Outcomes.
Tsumura T; Doi K; Marusawa H
Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954337
[TBL] [Abstract][Full Text] [Related]
14. A next-generation sequencing-based strategy combining microsatellite instability and tumor mutation burden for comprehensive molecular diagnosis of advanced colorectal cancer.
Xiao J; Li W; Huang Y; Huang M; Li S; Zhai X; Zhao J; Gao C; Xie W; Qin H; Cai S; Bai Y; Lan P; Zou Y
BMC Cancer; 2021 Mar; 21(1):282. PubMed ID: 33726687
[TBL] [Abstract][Full Text] [Related]
15. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
16. Tissue-Agnostic Drug Development: A New Path to Drug Approval.
Thein KZ; Lemery SJ; Kummar S
Cancer Discov; 2021 Sep; 11(9):2139-2144. PubMed ID: 34479971
[TBL] [Abstract][Full Text] [Related]
17. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
18. Tumor-Type Agnostic, Targeted Therapies: BRAF Inhibitors Join the Group.
Vranic S; Basu GD; Hall DW; Gatalica Z
Acta Med Acad; 2022 Dec; 51(3):217-231. PubMed ID: 36799315
[TBL] [Abstract][Full Text] [Related]
19. China special issue on gastrointestinal tumors-NTRK fusion in a large real-world population and clinical utility of circulating tumor DNA genotyping to guide TRK inhibitor treatment.
Qi C; Zhou T; Bai Y; Chen H; Yuan J; Zhao F; Liu C; Ma M; Bei T; Chen S; Zhao X; Chen C; Shen L
Int J Cancer; 2023 Dec; 153(11):1916-1927. PubMed ID: 36946696
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
